Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF

  • End date
    Jun 30, 2023
  • participants needed
  • sponsor
    VectivBio AG
Updated on 11 July 2021
Primary Contact
Yokohama Municipal Citizen's Hospital (7.8 mi away) Contact
+45 other location


The primary objective of the trial is the confirmation of the efficacy of apraglutide to evaluate the efficacy of weekly subcutaneous apraglutide in reducing parenteral support dependency.


This is an international, multicenter, double-blind, randomized, placebo-controlled, trial to evaluate the efficacy and safety of weekly SC injections of apraglutide in adult subjects with SBS-IF. The active pharmaceutical ingredient is apraglutide, a GLP-2 analogue.

The trial consists of a screening phase, a treatment phase of 48 weeks, and a safety follow-up phase. Trial participants will receive, after successful screening, once weekly apraglutide.

Condition Short Bowel Syndrome
Treatment apraglutide
Clinical Study IdentifierNCT04627025
SponsorVectivBio AG
Last Modified on11 July 2021


Yes No Not Sure

Inclusion Criteria

Signed informed consent for this trial prior to any trial specific assessment
Male and female subjects with SBS-IF, receiving parenteral support (PS), secondary to surgical resection of the small intestine with either stoma or colon-in-continuity (CIC)
Subject must require PS at least 3 days per work and be considered stable
No restorative surgery intended to change PS requirements in the trial period
Age 18 years at screening

Exclusion Criteria

Pregnancy or lactation
Major abdominal surgery in the last 6 months prior to screening
History of cancer (including colon carcinoma) or clinically significant lymphoproliferative disease within 5 years, except for adequately treated basal cell skin cancer
Evidence of active inflammatory GI conditions in the previous 6 months
Evidence of decompensated heart failure
Evidence of severe renal or hepatic impairment
Any previous use of growth factors such as growth hormone (GH), native GLP-2, GLP-1, or GLP-2 or GLP-1 analogues should be discussed with the Investigator
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note